These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36611001)

  • 61. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.
    Mizzi C; Dalabira E; Kumuthini J; Dzimiri N; Balogh I; Başak N; Böhm R; Borg J; Borgiani P; Bozina N; Bruckmueller H; Burzynska B; Carracedo A; Cascorbi I; Deltas C; Dolzan V; Fenech A; Grech G; Kasiulevicius V; Kádaši Ľ; Kučinskas V; Khusnutdinova E; Loukas YL; Macek M; Makukh H; Mathijssen R; Mitropoulos K; Mitropoulou C; Novelli G; Papantoni I; Pavlovic S; Saglio G; Setric J; Stojiljkovic M; Stubbs AP; Squassina A; Torres M; Turnovec M; van Schaik RH; Voskarides K; Wakil SM; Werk A; Del Zompo M; Zukic B; Katsila T; Lee MT; Motsinger-Rief A; Mc Leod HL; van der Spek PJ; Patrinos GP
    PLoS One; 2016; 11(9):e0162866. PubMed ID: 27636550
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
    Seeringer A; Kirchheiner J
    Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
    Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
    Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.
    Deneer VH; van Schaik RH
    Methods Mol Biol; 2013; 1015():345-54. PubMed ID: 23824868
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches.
    Ramudo-Cela L; Busto-Fernández F; Outeda-Macías M; Antolín S; Calvo-Martínez L; Martín-Herranz I
    Farm Hosp; 2021 Dec; 45(7):11-37. PubMed ID: 35379108
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacogenetics role in the safety of acenocoumarol therapy.
    Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
    Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying
    Stäuble CK; Lampert ML; Mikoteit T; Hatzinger M; Hersberger KE; Meyer Zu Schwabedissen HE
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204223
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fast Screening Technology for Drug Emergency Management: Predicting Suspicious SNPs for ADR with Information Theory-based Models.
    Liang Z; Liu J; Huang JX; Zeng X
    Comb Chem High Throughput Screen; 2018; 21(2):93-99. PubMed ID: 29336255
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project.
    Pratt VM; Turner A; Broeckel U; Dawson DB; Gaedigk A; Lynnes TC; Medeiros EB; Moyer AM; Requesens D; Vetrini F; Kalman LV
    J Mol Diagn; 2021 Aug; 23(8):952-958. PubMed ID: 34020041
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
    Yip VL; Pirmohamed M
    Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction.
    Carlquist JF; Horne BD; Mower C; Park J; Huntinghouse J; McKinney JT; Muhlestein JB; Anderson JL
    J Thromb Thrombolysis; 2010 Oct; 30(3):358-64. PubMed ID: 20499136
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency.
    Linder MW; Prough RA; Valdes R
    Clin Chem; 1997 Feb; 43(2):254-66. PubMed ID: 9023127
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The contribution of pharmacogenetics to pharmacovigilance.
    Bondon-Guitton E; Despas F; Becquemont L
    Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
    Hirata TDC; Dagli-Hernandez C; Genvigir FDV; Lauschke VM; Zhou Y; Hirata MH; Hirata RDC
    Mol Diagn Ther; 2021 Nov; 25(6):735-755. PubMed ID: 34357562
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.
    Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK
    Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
    Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P
    PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
    Sridharan K; Sivaramakrishnan G
    J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.
    Qayyum A; Najmi MH; Mansoor Q; Irfan M; Naveed AK; Hanif A; Kazmi AR; Ismail M
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):323-329. PubMed ID: 27879469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.